arrow
J

Juan Cosı́n-Sales

hospital arnau de vilanova
H指数:29
被引数:3,100

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical Characteristics, Cardiometabolic Risk Burden and Therapeutic Patterns in Patients Attending Cardiology Clinics in Spain: The RIESCAR Study

西班牙心脏病诊所就诊患者的临床特征、心血管代谢风险负担及治疗模式:RIESCAR研究

2026-10-150
OA
Extended Telemonitored Follow-Up After Acute Coronary Syndrome: A Healthcare Pathway That Improves Cardiovascular Prevention and Patient Experience, and Reduces Outpatient Visits

急性冠状动脉综合征后的扩展远程监测随访:一种改善心血管预防与患者体验并减少门诊就诊的医疗路径

2026-03-030
OAAI
Impact of therapeutic inertia in lipid-lowering therapy in patients at very high cardiovascular risk

极高风险心血管病患者中降脂治疗惰性的影响

2025-11-012
PRE
Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry

预测利伐沙班治疗的房颤患者的血型出血和眼眶出血风险评分的性能: 来自EMIR前瞻性注册的观察结果

2022-11-019
PRE
Use of rivaroxaban attenuates renal function impairment in patients with atrial fibrillation: insights of the EMIR study
2022-04-145
PRE
Stratification and management of cardiovascular risk in cancer patients. A consensus document of the SEC, FEC, SEOM, SEOR, SEHH, SEMG, AEEMT, AEEC, and AECC

癌症患者心血管风险的分层和管理。SEC、FEC、SEOM、SEOR、SEHH、SEMG、AEEMT、AEEC和AECC的共识文件

2021-05-0121
PRE
Telemedicine consultation for the clinical cardiologists in the era of COVID-19: present and future. Consensus document of the Spanish Society of Cardiology
2020-11-0133
OAAI
Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology
2020-09-0187
OAAI